Anti-Human HER-2 (Trastuzumab) - APC

Leinco Technologies
Product Code: LEI-LT1503
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT1503-50ug50 ug£265.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: 4D5-8
Regulatory Status: RUO
Target Species: Human
Applications:
  • Flow Cytometry
  • Immunohistochemistry (IHC)
Shipping:
2-8°C
Storage:
This Allophyc°Cyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Human epidermoid carcinoma cells (A431) over-expressing EGFR.
Long Description:
Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
NCBI Gene:
2064
Target:
HER-2/neu

References

1. Fendly, B. et al. (1990) Cancer Research 50: 1550-1558. 2. McBride, H. et al. (2019) Pharm Res. 36(12): 177. 3. Zielinski, C. et al. (1997) Int. J. Cancer 73: 875?879 4. Valone, FH. et al. (1995) J. Clin. Oncology 13 (9): 2281-92. 5. Hynes, NE. et al. (1993) Br J Cancer. 68(6): 1140?1145.